Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350214 | 1.00 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4455195 | 1.00 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9980186 | 0.83 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7924715 | 0.83 | SMN1; SMN2 (0.42) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL2355614 | 0.82 | SMN1; SMN2 (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL2355611 | 0.82 | SMN1; SMN2 (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Methoxymethane SCHEMBL7986326 | 0.81 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Methoxymethane SCHEMBL7986329 | 0.81 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL14537498 | 0.81 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL1564513 | 0.80 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461475-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | Wyeth LLC (US) | 2019-04-03 | — | — | EP | claimed |
| EP-2004147-B1 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | WYETH LLC (US) | 2019-01-02 | — | — | EP | claimed |
| US-9238073-B2 | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive | WYETH LLC (US) | 2016-01-19 | — | — | US | claimed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| CN-101420936-A | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive | WYETH CORP (US) | 2009-04-29 | — | — | CN | claimed |
| EP-2004147-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | Wyeth a Corporation of the State of Delaware (US) | 2008-12-24 | — | — | EP | claimed |
| WO-2007120725-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | WYETH (US) | 2007-10-25 | — | — | WO | claimed |
| US-20070243140-A1 | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive | HALEON US HOLDINGS LLC | 2007-10-18 | — | — | US | claimed |
| CN-115286671-B | Oligonucleotide-thiazolidine compound, synthesis method and application | 康龙化成(宁波)科技发展有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| CN-110809468-A | Method of inducing chondrogenesis | 斯克利普斯研究所 | 2020-02-18 | — | — | CN | disclosed |
| US-10307485-B2 | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive | WYETH LLC (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3461475-A1 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | Wyeth LLC (US) | 2019-04-03 | — | — | EP | disclosed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-2004147-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | Wyeth a Corporation of the State of Delaware (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120725-A2 | PHARMACEUTICAL COMPOSITION CONTAINING SYMPATHOMIMETIC AMINE SALT AND CO-DISTILLABLE ADDITIVE | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070243140-A1 | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive | HALEON US HOLDINGS LLC | 2007-10-18 | — | — | US | disclosed |
| US-4245104-A | Isoxazolines and isoxazolidines | HOFFMANN-LA ROCHE INC. (US) | 1981-01-13 | — | — | US | disclosed |
| EP-0011777-A1 | Novel process for the manufacture of thiophene derivatives suited for the manufacture of biotin, process for the manufacture of biotin and novel intermediates in this process | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | ATP6V1B1, GLS, REN | KDM4E 3485/4885MAPT 2127/4885THRB 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.